Jackson Wealth Management’s VistaGen Therapeutics VTGN Stock Holding History

Jackson Wealth Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-795	Closed	-$2.97K	–	137
2023 Q1	$2.97K	Buy	+795	New	+$4.17K	﹤0.01%	120
2022 Q4	–	Sell	-558	Closed	-$3K	–	112
2022 Q3	$3K	Sell	558 -9	-2%	-$89	﹤0.01%	101
2022 Q2	$15K	Buy	567 +21	+4%	+$741	0.01%	87
2022 Q1	$20K	Hold	546	–	–	﹤0.01%	110
2021 Q4	$32K	Buy	546 +4	+0.7%	+$260	﹤0.01%	113
2021 Q3	$0	Buy	542 +96	+22%	+$8.34K	﹤0.01%	123
2021 Q2	$42K	Buy	+446	New	+$33K	0.01%	123

Other funds holding VTGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jackson Wealth Management's VTGN Position: Q2 2023 in Review

Jackson Wealth Management sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 795 shares — an estimated $2.97K sold.

Jackson Wealth Management first reported a position in VTGN in Q2 2021 and held it in 7 quarters. The position peaked at $42K in Q2 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

Jackson Wealth Management reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
Jackson Wealth Management sold 795 VistaGen Therapeutics shares in Q2 2023, an estimated $2.97K.
Jackson Wealth Management first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 7 quarters.
Jackson Wealth Management's VistaGen Therapeutics position peaked at $42K in Q2 2021.
33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Jackson Wealth Management's 13F filing for Q2 2023, filed 2 Aug 2023.